Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

liposomal CMTR2 inhibitor AT-1965

A liposomal formulation containing an inhibitor of cap-specific mRNA (nucleoside-2-O-)-methyltransferase 2 (cap-methytransferase 2; CMTR2; MTR2; FTSJD1), with potential immunomodulating and antineoplastic activities. Upon administration, liposomal CMTR2 inhibitor AT1965 targets, binds to, and inhibits the activity of CMTR2. This causes the innate immune sensors to recognize the mRNA as non-self and results in an anti-viral immune response leading to the activation of B cells and resulting in a B-cell-mediated immune response against tumor cells. This induces tumor cell apoptosis and decreases tumor growth. CMTR2, a key protein in marking newly-synthesized RNA as self, plays a key role in tumor host immunity evasion. Increased expression of CMTR2 correlates with poor prognosis. It is overexpressed in a variety of tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:AT 1965
AT-1965
AT1965
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search